Business news and discussion on TalkFuse.
Pizza chains are under pressure. GLP-1 use is only one part of the problem
Pizza chains face tougher competition as delivery apps give diners more cuisines to choose from, while rising prices make pizza less attractive to budget-conscious customers. The category is also adapting slowly to changing nutrition preferences, and GLP-1 medicines may be contributing to weaker demand, although they are only one part of the pressure.
A large cheese pizza now costs almost $17 on average, while frozen pizza sales rose 2.9% over the 52 weeks to 7 November compared with the same period in 2022. PwC found that spending at pizza quick-service restaurants fell 22.2% per GLP-1 household after six to eight months on the medicines; overall pizza servings are down about 1% this year. Chains are responding with new products, meal deals and operational changes, but an industry adviser said consumers still love pizza.
In short
- Delivery choices and higher prices are squeezing pizza chains.
- GLP-1 use is one factor among several affecting demand.
- Pizza servings are down about 1% this year.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Pizza chains face pressures beyond GLP-1 medicines, including delivery apps widening the choice of cuisines and higher prices pushing budget-conscious diners towards alternatives such as frozen pizza. The decline in pizza servings is modest, and consumers’ continuing affection for pizza, alongside chains’ efforts to offer new products and meal deals, suggests the category can adapt.
The case against
GLP-1 use may be a more significant challenge for pizza chains than the broader pressures imply: PwC found that spending at pizza quick-service restaurants fell 22.2% per GLP-1 household after six to eight months on the medicines. If use grows and customers change their eating habits, chains may face sustained demand losses, while new products and discounts may not be enough to offset them.